ANI Pharmaceuticals Inc (NASDAQ:ANIP) CEO Arthur Przybyl sold 9,595 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $71.10, for a total value of $682,204.50. Following the sale, the chief executive officer now directly owns 222,994 shares of the company’s stock, valued at $15,854,873.40. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Arthur Przybyl also recently made the following trade(s):
- On Wednesday, May 15th, Arthur Przybyl sold 30,000 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $70.07, for a total value of $2,102,100.00.
- On Tuesday, March 19th, Arthur Przybyl sold 27,625 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $63.53, for a total value of $1,755,016.25.
ANIP traded down $0.63 during mid-day trading on Wednesday, reaching $69.14. The stock had a trading volume of 104,701 shares, compared to its average volume of 87,476. The firm has a market capitalization of $836.09 million, a price-to-earnings ratio of 15.00 and a beta of 2.37. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.67 and a current ratio of 0.92. ANI Pharmaceuticals Inc has a 52 week low of $36.92 and a 52 week high of $74.00.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 EPS for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.25. The firm had revenue of $52.90 million for the quarter, compared to analyst estimates of $50.57 million. ANI Pharmaceuticals had a return on equity of 28.63% and a net margin of 6.58%. The business’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period last year, the company earned $1.32 EPS. As a group, research analysts forecast that ANI Pharmaceuticals Inc will post 5.97 EPS for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Financial Gravity Wealth Inc. bought a new position in shares of ANI Pharmaceuticals in the 1st quarter worth $54,000. Quantamental Technologies LLC boosted its position in shares of ANI Pharmaceuticals by 169.4% in the 1st quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock worth $61,000 after purchasing an additional 542 shares during the last quarter. South Dakota Investment Council bought a new position in shares of ANI Pharmaceuticals in the 4th quarter worth $45,000. BNP Paribas Arbitrage SA boosted its position in shares of ANI Pharmaceuticals by 55,466.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock worth $118,000 after purchasing an additional 1,664 shares during the last quarter. Finally, Truvestments Capital LLC bought a new position in shares of ANI Pharmaceuticals in the 1st quarter worth $140,000. Hedge funds and other institutional investors own 60.02% of the company’s stock.
ANIP has been the topic of a number of recent research reports. ValuEngine upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 4th. BidaskClub upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, February 14th. Raymond James set a $73.00 price objective on ANI Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, February 28th. TheStreet upgraded ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Tuesday, March 19th. Finally, Zacks Investment Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $76.00 price objective on the stock in a research report on Thursday, March 28th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. ANI Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $84.25.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Further Reading: Institutional Investors
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.